GlassScriptPrepare for your visit
Michael James Dennis
Medical Oncology · Boston, MA · NPI 1629519855
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$15,452.36
in general payments reported to CMS, 2019-2025 · $4,940 in 2025
The $4,940 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Who reported paying
General payments only, top 6 by amount.
- Dr.Reddy'S Laboratories,INC. $12,731.97
- Coherus Oncology, INC. $2,200.77
- Blueprint Medicines Corporation $129.30
- Merck Sharp & Dohme LLC $124.99
- Foundation Medicine, INC. $123.82
- E.R. Squibb & Sons, L.L.C. $121.35
Drugs and devices associated with these payments
Loqtorzi Keytruda
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Michael Dennis listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/3617167/michael-james-dennis